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Abstract
Anti-mullerian hormone (AMH) is a glycoprotein of the TGF-β cytokine super-
family that regulates the development of the mammalian reproductive system, 
as well as the functioning of mature gonads. Recombinant AMH (rAMH) is also 
able to induce apoptosis of malignant cells bearing AMH type II receptors (MIS-
RII) on the surface. Development of rAMH-based anticancer drugs is hampered 
by the lack of accurate information about the tissues where the AMH active 
form is generated and about the enzyme that activates the hormone by specific 
proteolysis. According to one hypothesis, the proteolytic processing of the hor-
mone is autocatalytic. The goal of this work was to investigate the proteolytic 
activity of rAMH and its biologically active form — C-terminal AMH fragment 
(C-AMH). We showed that two forms of the hormone possess both autopro-
teolytic activity and the ability to influence the structure of other proteins. A 
full-length molecule of the hormone, as well as C-AMH, also forms complexes 
with aprotinin, an inhibitor of trypsin-like serine proteases. We determined that 
aprotinin competes for binding to C-AMH with antibodies blocking C-AMH inter-
action with MISRII. The obtained data suggest that AMH has proteolytic proper-
ties and that the site of specific AMH cleavage is involved in the interaction of 
the hormone with a specific receptor.
Keywords: anti-mullerian hormone, AMH, aprotinin, autoproteolysis, MIS, pro-
tease, recombinant protein.
Introduction
Anti-mullerian hormone (AMH — a substance inhibiting Mullerian ducts, Mul-
lerian inhibitory substance, MIS) is one of the least studied glycoproteins of the 
TGF-β superfamily. It is both an embryonic and postnatal regulator of the mam-
malian reproductive system development and functioning (Gukasova and Sev-
erin, 2005). Recombinant AMH (rAMH) is known to induce apoptosis in cells of 
a number of human tumors (Donahoe et al., 2003; Jung et al., 2016). The AMH 
molecule with a mass of about 140 kDa is a homodimer, both monomers con-
taining a proteolytic cleavage site in their sequence located between the residues 
Arg427 and Ser428. Specific proteolysis of the full-length hormone molecule at 
this site leads to its cleavage to N- and C-terminal homodimers with molecu-
lar masses of about 115 and 25 kDa, respectively (Gukasova and Severin, 2005). 
Under physiological conditions, these AMH fragments form a non-covalently 
associated complex after proteolysis of the prohormone molecules. It has been 
shown that specific proteolysis is crucial for the activation of the hormone. This 
fact has been confirmed by experiments with the mutant AMH form without a 
specific proteolysis site. The mutant protein does not exhibit biological activity in 
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the growth inhibition test of the rat Mullerian duct or-
gan culture (Cate, Donahoe and MacLaughlin, 1990). It 
is also known that, unlike the N-terminal, the C-termi-
nal homodimer of AMH (C-AMH) is biologically active 
(Pankhurst, Leathart, Batchelor and McLennan, 2016).
The AMH signaling pathway has been well stud-
ied; it starts from the interaction of the hormone with 
AMH type II receptor (MISRII), which further leads to 
heteromerization of the AMH type I receptor (MISRI) 
and MISRII and induction of the proapoptotic signal-
ing cascade provided by Smad family proteins (Teixeira, 
Maheswaran and Donahoe, 2001). The MISRI receptor 
belongs to the family of transmembrane serine / threo-
nine protein kinases similar to the activin receptor (ac-
tivin receptor-like kinases, ALKs). Presumably, ALK2, 
ALK3  and ALK6  (also known as ACVR1, BMPR1A 
and BMPR1B, respectively) can play the role of MISRI 
(Orvis et al., 2008; MacLaughlin and Donahoe, 2010; 
Sèdes et al., 2013). Unlike type I receptors, MISRII is 
exclusively AMH-specific (Pankhurst, Leathart, Batch-
elor and McLennan, 2016), MISRII expression is tissue-
specific (Lee and Donahoe, 1993; Teixeira, Maheswaran 
and Donahoe, 2001) and overexpression of this recep-
tor is a characteristic of a number of malignant cells 
(MacLaughlin and Donahoe, 2010; Kim, MacLaughlin 
and Donahoe, 2014). For this reason, it can serve as a 
target for induction of apoptosis in MISRII-positive tu-
mor cells as a result of interaction with rAMH or spe-
cific antibodies (Estupina et al., 2017; Deshayes et al., 
2018) or be targeted for an attack of AMH complexed 
with different cytostatics (MacLaughlin and Donahoe, 
2010; Kim, MacLaughlin and Donahoe, 2014). Cancer 
treatment based on a targeted effect on MISRII seems to 
be a more effective alternative to the traditional one and 
will significantly reduce the dose of antineoplastic drugs 
due to their targeted delivery to the malignant cells (Ma-
cLaughlin and Donahoe, 2010).
The exact mechanism of hormone binding, as well 
as the structure of the interaction site, is still unknown. 
Most researchers take the position that MISRII mole-
cules are not randomly distributed in the cell membrane 
but form homodimeric complexes even before interact-
ing with the ligand (Hirschhorn et al., 2015). Thus, AMH 
interacts with the MISRII dimer, which then forms a li-
gand-receptor complex with the MISRI dimer (Kikuchi 
and Hamaguchi, 2013). However, it is still unclear which 
hormone derivatives are capable of triggering this sig-
naling pathway in vivo.
The question of where specific proteolysis of AMH 
molecule occurs in vivo and what enzyme is required for 
cleavage also remains open. Some authors suggest that 
AMH is activated by cleavage exclusively in biosynthesis 
and secretion, but not in blood. In this case, hormone 
cleavage occurs in gonads, and both uncleaved prohor-
mone and non-covalently associated complex of the N- 
and C-terminal AMH fragments enter the circulation 
(Pankhurst, Leathart, Batchelor and McLennan, 2016). 
According to another hypothesis, specific proteolysis 
of AMH can occur both in the bloodstream under the 
action of plasmin and in the gonads under the action 
of proprotein-convertase family enzymes such as furin 
and PC5  (Ragin et al., 1992; Nachtigal and Ingraham, 
1996). Finally, the hormone cleavage at a specific site 
may be associated with its entry into the target tissues 
and interaction with the AMH receptors type I and 
type  II  — MISRI and MISRII, respectively (Di Clem-
ente et al., 2010). In this case, specific proteolysis of the 
AMH molecule needs to be autocatalytic — that is, this 
process does not require the involvement of any other 
enzymes. Many different proteins are known to activate 
through autoproteolytic processing, in particular, pep-
sinogen (Dunn B. M., 2001), nucleoporin (Rosenblum 
and Blobel, 1999), Hedgehog family factors and glyco-
sylasparaginases (Perler, Xu and Paulus, 1997). Clarify-
ing whether the AMH molecule has its own proteolytic 
activity will make it possible to refresh a look at the bio-
chemistry and pharmacodynamics of this substance, as 
well as to optimize the rAMH producing method for an-
tineoplastic drugs development.
The goal of this work was to study the stability of 
highly purified preparations of rAMH and to determine 
whether prohormone and its biologically active form, 
the C-terminal fragment, have proteolytic activity.
Materials and Methods
Preparations of prohormone, half-cleaved rAMH (a 
form containing one monomer protealyzed at a specific 
site) and C-AMH, characterized by a purity of about 
96 %, were obtained previously from the culture fluid of 
the CHO line producer cells, transfected with the hu-
man AMH gene (producer strain CHO-MIS 26 (Rak et 
al., 2017)), by the method of tandem immunoaffinity 
and reversed-phase chromatography according to the 
developed method (Rak et al., 2019). In addition, previ-
ously obtained highly purified preparations of recombi-
nant human heat shock protein 70 (HSP70) were used in 
the experiments (Ischenko et al., 2015). We also used the 
aprotinin solution for intravenous administration with a 
concentration of 10,000 U / ml and following previously 
obtained mouse monoclonal antibodies:
• ACMIS-3  and ACMIS-4  (Rak, Trofimov, Kolobov 
and Ischenko, 2018), specific to different C-AMH 
epitopes, but not interacting with the uncleaved 
hormone. Using these antibodies, ACMIS-3-Px 
and ACMIS-4-Px conjugates with horseradish per-
oxidase (Sigma, United States) were prepared ac-
cording to the attached protocol. An enzyme im-
munoassay test system (ACMIS-3)  — C-AMH  — 
(ACMIS-4-Px) based on these antibodies was used 







for quantitative detection of C-AMH in a hetero-
geneous sandwich enzyme-linked immunosorbent 
assay (ELISA);
• M2  (Rak et al., 2019), recognizing the full-length 
AMH and its derivatives, containing the N-termi-
nal fragment, and the M2-Px — derivative of these 
antibodies. These antibodies were used to develop 
the ELISA system (ACMIS-3) — AMH — (M2-Px), 
which was used for the quantitative detection of 
half-cleaved rAMH;
• I4 (Rak et al., 2017), specific to the Fc-fragment of 
human IgG1 immunoglobulins;
• CC3-4  (Kartuzova et al., 2016), recognizing the 
conformational epitope of the human complement 
C3 component.
The biological activity of rAMH was evaluated by the 
ability of the hormone to bind to the extracellular part of 
the specific AMH receptor type II — MISRII (Rak et al., 
2017). For this purpose, a previously developed enzyme 
immunoassay test system (Rak et al., 2019) was used. The 
keystone of this ELISA system is the recombinant chime-
ric protein MISRII + Fc, consisting of the extracellular 
part of MISRII and Fc fragment of human IgG1. Antibody 
I4 and the peroxidase conjugate ACMIS-4-Px were also 
used in the test system. At the first stage of the analysis, 
Corning polystyrene plates (Sigma, United States) were 
treated with I4 antibodies in the coating solution (20 mM 
borate buffer, pH 8.0, containing 0.15 M NaCl) at a con-
centration of 1.5 μg / ml for 20 hours in a humid chamber 
at room temperature. At the end of the sorption, the plates 
were treated with wash buffer (20 mM borate buffer, pH 
8.0, containing 0.15 M NaCl and 0.05 % Tween-20). At the 
next stage, the chimeric MISRII-containing construct so-
lution (100 ng / ml) was added into the wells as a specific 
acceptor for rAMH preparations. After the test samples 
were added, detection of bound rAMH was performed 
using ACMIS-4-Px antibodies (0.25 μg / ml). The ELISA 
was performed by a standard method using tetramethyl-
benzidine substrate solution (HEMA, Russia) and BioRad 
Model 680 microplate reader (BioRad, USA) at a wave-
length of 450 nm. Schematically, the test system for the 
rAMH biological activity evaluation can be described as 
I4 — (MISRII + Fc) — rAMH — (ACMIS-4-Px). We used 
this ELISA system to accurately determine the concentra-
tion of the biologically active hormone in various prepa-
rations and biological fluids.
The interaction of C-AMH with aprotinin was 
also analyzed in solid-phase ELISA. At first, plates were 
treated with aprotinin in the coating solution at a con-
centration of 1.5 μg / ml for 20 hours in a humid cham-
ber at room temperature. At the end of the sorption, the 
plates were treated with wash buffer. Then two-fold di-
lutions of rAMH in wash buffer containing 10 mg / ml 
bovine serum albumin (BSA) were added at 100 μl per 
well. The plates were incubated for 1 hour with stirring 
at 37 °C. Then a solution of ACMIS-4-Px antibodies 
(0.25 μg / ml) was added to the washed plates. The plates 
were incubated for 1 hour with stirring at 37 °C, and fi-
nally they were thoroughly washed and stained with a 
tetramethylbenzidine substrate solution (HEMA, Rus-
sia). The ELISA was performed by a standard method 
using a BioRad Model 680 microplate reader (BioRad, 
USA) at a wavelength of 450 nm.
Analysis of rAMH preparations was performed by 
electrophoresis of proteins in a polyacrylamide gel with 
sodium dodecylsulphate (SDS-PAGE) and with or with-
out a reducing agent (β-mercaptoethanol) according 
to the previously described method (Walker, 1984). In 
this work, a running gel with a gradient concentration 
of acrylamide of 4–20 % and a stacking gel with a con-
centration of 5 % were used. The samples were prepared 
by incubation of protein solution (1–2 mg / ml) at 95 °C 
for 5 min in the presence of β-mercaptoethanol (at final 
concentration 2 %) or without it, then 15 μl of each sam-
ple was loaded into the gel. SDS-PAGE was performed 
by the BioRad MiniProtean Tetra Cell system (BioRad, 
USA) at a voltage of 40 V per gel for 20 minutes and then 
at a current of 200 mA until the end of the electropho-
resis. To visualize the results, the gel was stained with 
Coomassie G-250, followed by washing with a 5 % solu-
tion of acetic acid at room temperature.
To perform the affinity chromatography of half-
cleaved rAMH, an affinity sorbent was prepared by 
immobilization of aprotinin (with a loading of 10  mg 
/ ml) on cyanbrom-activated sepharose FF (Pharmacia, 
Sweden) according to the manufacturer’s protocol. The 
column containing the sorbent was equilibrated with 
20  mM phosphate buffer, pH 7.4, containing 0.15  M 
NaCl. At the first stage of chromatography, 100  μg of 
rAMH was loaded to a 1 ml column for sorption. After 
washing the column with an equilibration buffer and a 
buffer containing 1 M NaCl, rAMH was eluted from the 
sorbent with a solution of 0.1  M glycine, pH 2.5. De-
tection of components during the chromatography was 
performed at a wavelength of 280 nm.
The quantitative data are given as mean ± s.e.m. 
from two independent experiments with three techni-
cal replicates (n = 6). Compliance with the normal dis-
tribution was checked by Shapiro-Wilk’s test. The sig-
nificance of differences was assessed by Student’s t-test 
for paired data, since all the data were normally distrib-
uted. The level of significance was set at p<0.05. Statisti-
cal analysis was performed using Statistica 10 software.
Results and Discussion
According to previously obtained data (Rak et al., 2019), 
the uncleaved rAMH (prohormone) contained in the 
highly purified sterile preparation undergoes proteolysis 
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during long-term storage; it leads to C-AMH formation. 
The prohormone is not capable of binding to the recep-
tor; however, as C-AMH accumulates in the solution, the 
biological activity of the protein contained in the sample 
increases and reaches a maximum on the 30th day of 
storage (Rak et al., 2019). Here, we first studied the ef-
fect of aprotinin — a nonspecific polyvalent trypsin-like 
serine protease inhibitor — on rAMH proteolysis dur-
ing storage. It was shown that the addition of aprotinin 
at a final concentration of 5  μg /  ml blocks the prote-
olysis of prohormone, the formation of C-AMH and the 
manifestation of the biological activity of the substance, 
which is shown in Figure 1. Electrophoretic analysis was 
performed under non-reducing conditions. To evaluate 
the rAMH activity, we used ELISA system I4-(MISRII + 
Fc) — rAMH — ACMIS-4-Px.
As can be seen from Figure 1, during storage of 
rAMH, an accumulation of the C-terminal fragment 
fraction in the preparation occurs (Fig. 1, a), while in 
the presence of aprotinin uncleaved rAMH is stable 
(Fig. 1, b). The quantitative analysis of C-AMH accu-
mulation dynamics is presented in Figure 1, c.
It was previously shown that C-AMH, like the full-
length form of the hormone, undergoes spontaneous 
limited proteolysis at a specific site (leucine motif). In 
this case, the smallest fragment with a molecular mass of 
Fig. 1. The effect of aprotinin on the rAMH proteolysis during storage. a — electro-
phoregram of the initial hormone (1) and rAMH after incubation in 20 mM phos-
phate buffer, pH 7.4, for 15 (2) and 25 days (3) at + 37 °С, M — molecular weight 
marker; b — electrophoregram of the rAMH preparation with aprotinin (5 μg / ml) 
added immediately after the purification: before the storage (1), after incubation in 
20 mM phosphate buffer, pH 7.4, at + 37 °С for 15 (2 ) and 25 days (3); M — molecu-
lar weight marker, the arrow indicates the aprotinin localization in the gel; c — the 
accumulation of the biologically active protein in highly purified rAMH preparation 
during incubation in 20 mM phosphate buffer, pH 7.4, at 37 °C. The significance of 
differences was estimated using Student’s t-test: * — p<0.05 compared to day 5.







Fig. 2. The C-AMH proteolysis in presence or absence of aprotinin. a — electrophoregram of the initial 
C-AMH (3, 8) and after incubation in 20 mM phosphate buffer, pH 7.4, for 15 (4, 9) and 25 days (5, 10) 
at + 37 °С, C-AMH freshly mixed with aprotinin (5 µg / ml) (1, 5) and after incubation for 25 days (2, 6), 
M — molecular weight marker, arrows indicate the aprotinin bands; b — dependence of the absorbance 
intensity on the concentration of initial and proteolyzed C-AMH, determined using the test system I4 — 
(MISRII + Fc) — rAMH — ACMIS-4-Px. The significance of differences was estimated using Student’s t-test: 
* — p<0.05 compared to C-AMH concentration 6.25 ng / ml.
Fig. 3. Dependence of the absorbance intensity on the concentration of AMH forms: half-cleaved hormone 
(detected by M2-Px) and C-AMH (detected by ACMIS-4-Px) interacting with aprotinin immobilized in the 
plate (1.5 μg / ml). * — p<0.05 compared to AMH concentration 0.25 μg / ml.
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about 6 kDa is formed, and C-AMH biological activity 
disappears (Rak et al., 2019). 
In this work, the inhibitory effect of aprotinin on 
C-AMH specific proteolysis was also studied. In order to 
show whether the inhibitory effect of aprotinin extends 
to C-AMH degradation and to study the effect of the in-
hibitor on the activity loss of this AMH derivative, the 
sample was incubated with or without the aprotinin. It 
was found that aprotinin, as well as in the case of a pro-
hormone, prevents the proteolysis of C-AMH (Fig. 2).
The interaction of aprotinin with C-AMH and half-
cleaved full-length hormone (containing one monomer 
proteolyzed) was studied in solid-phase ELISA. It was 
shown that C-AMH, as well as half-cleaved rAMH, is 
able to form the specific complexes with aprotinin im-
mobilized in the plate (Fig. 3). Note, that the intensity 
of C-AMH binding with immobilized aprotinin was sig-
nificantly higher.
In order to find out whether C-AMH is capable of 
interacting not only with immobilized aprotinin, but 
Fig. 4. Interaction of C-AMH with solvated aprotinin. a — the effect of C-AMH concentration and the presence of 
protease inhibitors or competitor on the binding of C-AMH with immobilized aprotinin (1.5 μg / ml); a decrease 
in the intensity of C-AMH interaction with immobilized aprotinin in the presence of dissolved one is showed. 
b — the effect of C-AMH concentration and the presence of protease inhibitors on the binding of C-AMH with 
immobilized chimeric construct MISRII + Fc (1.5 μg / ml); decrease in signal intensity in the presence of aprotinin, 
caused by the competition between MISRII+Fc and aprotinin for binding to C-AMH, is shown. The significance of 
differences was estimated by Student’s t-test: * — p<0.05 compared to the controls (w/o competitor).







also with that present in the solution, a competitive 
ELISA was performed. The C-AMH double dilutions 
were preincubated for 15  min with fixed concentra-
tions of aprotinin (10 μg / ml) and possible competitors 
of C-AMH binding with aprotinin (protease inhibitors 
PMSF and benzamidine, and chimeric protein MISRll 
+ Fc; 1 mM, 5 mM and 10 µg / ml, respectively). Then 
the samples were transferred into the plate wells con-
taining immobilized aprotinin. C-AMH was detected 
by the subsequent addition of the peroxidase conjugate 
ACMIS-4-Px. The ELISA results presented in Figure 
4 indicate that not only immobilized, but also solvated 
aprotinin is capable of binding to C-AMH present in the 
solution. Competition between the solvated aprotinin 
and immobilized one for C-AMH binding results in a 
decrease in the C-AMH detection intensity by ACMIS-
4-Px conjugate. It is shown (Fig. 4, a) that other protease 
inhibitors, namely PMSF and benzamidine, present in 
the solution do not have this effect.
In another variant of the analysis, the presence of 
competition between aprotinin and the chimeric receptor-
containing protein MISRII + Fc for binding to C-AMH was 
found. In this case, double dilutions of C-AMH were pre-
incubated with aprotinin, PMSF and benzamidine at the 
same fixed concentrations as in the previous experiment, 
and then the mixes were added to the immobilized con-
struct MISRII + Fc (Fig. 4, b). At the last stage of this ELI-
SA, peroxidase conjugate ACMIS-4-Px was used to detect 
C-AMH. It was shown that in the presence of aprotinin, 
the intensity of C-AMH interaction with ACMIS-4-Px de-
creases, which was not observed when adding other non-
specific protease inhibitors PMSF and benzamidine.
An analysis of ACMIS-3 specificity, which was per-
formed in a previous study (Rak et al., 2017), showed 
Fig. 5. Detection of half-cleaved rAMH by peroxidase conjugates ACMIS-3-Px and ACMIS-4-Px with immobilized: a — aprotinin (1.5 μg / ml); b — 
M2 antibodies (1.5 μg / ml). * — p<0.05 compared to half-cleaved rAMH concentration 0.25 μg / ml.
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Fig. 6. Affinity chromatography of half-cleaved rAMH on aprotinin-sepharose. For quantitative detection 
of the hormone, the ELISA system (ACMIS-3) — rAMH — (M2-Px) was used. The significance of differences 
was estimated using Student’s t-test: * — p<0.05 compared to initial concentration.
Fig. 7. C-AMH is able to catalyze the proteolysis of other proteins. a — electrophoregram of 
HSP70 and C-AMH mix after incubation for 7 (1) and 15 days (2), as well as the initial HSP70 
preparation (3) and HSP70 after 15 days of incubation (4), M — molecular weight marker; 
b — electrophoregram of CC3-4 and C-AMH mixture after incubation for 15 days (1) and the 
initial CC3-4 preparation (2), M is the molecular weight marker. Electrophoretic analysis was 
performed under the non-reducing conditions. The black arrows indicate the aprotinin local-
ization in the gel, and the grey arrow indicates the area corresponding to immunoglobulins.







that these antibodies against C-AMH are able to inhibit 
the interaction of the hormone with AMH receptor type 
II (MISRII). As can be seen from Figure 4, b, aprotinin 
has a similar effect.
To test the hypothesis that ACMIS-3 antibodies and 
aprotinin bind to the same C-AMH epitope involved in 
interacting with the MISRII, the ELISA using full-length 
one-chain cleaved (half-cleaved) rAMH was performed. 
A series of the hormone dilutions were added into the 
wells with immobilized aprotinin (Fig. 5, a) or M2 an-
tibodies recognize the epitope within N-terminal frag-
ment of rAMH (Fig. 5, b). The bound hormone was 
detected by two conjugates: ACMIS-3-Px and ACMIS-
4-Px.
It can be seen that in the case of M2 antibody immo-
bilization, full-length rAMH cleaved in one chain can be 
detected using both the ACMIS-3-Px and ACMIS-4-Px 
conjugates (Fig. 5, b). However, under immobilization of 
aprotinin in the wells of the plate, hormone detection is 
possible only with the aid of the ACMIS-4-Px conjugate, 
since the epitope recognized by the antibodies ACMIS-
3-Px and involved in the interaction of rAMH with MIS-
RII is occupied by aprotinin. (Fig. 5, a). These data sug-
gest that the sites of the AMH molecule involved in the 
interaction of the hormone with MISRII and aprotinin 
are identical.
To study the ability of rAMH to bind to aprotinin in 
a flow system, 100 μg of the half-cleaved hormone was 
analyzed by affinity chromatography on an aprotinin-
sepharose column. Such sorbents have often been used 
for the purification of various proteins to remove the ser-
ine proteases from preparations (Shikimi and Kobayas-
hi, 1980; Schmitt, Goetschel, Römmelt and Adler, 1990). 
The results of affinity chromatography are presented in 
Figure 6. It can be seen that the content of half-cleaved 
rAMH in the eluate is about 80 % of hormone applied 
on the column. These data confirm the specificity of the 
interaction of the hormone with aprotinin.
In order to test the C-AMH ability to catalyze the 
proteolysis of other proteins, the hormone was added to 
the solution of highly purified human recombinant heat 
shock protein 70 (HSP70) in a weight ratio of 1:10. The 
mixture was incubated for 30 days at + 37 °C. The result 
of the experiment is shown in Figure 7, a. The appear-
ance of additional bands on the electrophoregram indi-
cates that C-AMH is involved in the proteolysis of the 
HSP70 molecule (Fig. 7, a).
A similar experiment was performed with mouse 
immunoglobulins CC3-4, specific to human comple-
ment C3 component. C-AMH was added to the CC3-
4 solution (also in a weight ratio of 1:10), and this mix-
ture was incubated at + 37 °C. As follows from the results 
shown in Figure 7, b, in the presence of C-AMH: new 
bands appear, and the area corresponding to immuno-
globulins becomes more diffuse (Fig. 7, b). These data 
prove the presence of the proteolytic effect of C-AMH 
on CC3-4 antibodies. Affecting factors, as well as the se-
quence of the fragments that are formed and the site of 
C-AMH action will have to be clarified in the course of 
further experiments.
Conclusions
In this study, the proteolytic properties of the activated 
AMH (C-AMH) and full-length hormone were first 
described in vitro. Inhibition of the proteolytic activity 
of both hormone forms by aprotinin  — the inhibitor 
of trypsin-like serine proteases — was found. The pro-
teolytic activity of C-AMH against human HSP70 and 
mouse immunoglobulins CC3-4 was shown. We dem-
onstrated that half-cleaved rAMH and C-AMH are able 
to interact with both immobilized and dissolved apro-
tinin; this protease inhibitor also competes for binding 
to the hormone with antibodies that block the interac-
tion of C-AMH with MISRII. The data obtained sup-
port the autocatalytic mechanism of AMH cleavage and 
prove the ability of AMH to catalyze the proteolysis of 
other proteins as well as the fact that the site of AMH 
specific proteolysis may be involved in the interaction of 
the hormone with type I and II receptors exposed on the 
surface of target cells.
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